Keyphrases
Repaglinide
100%
Neutral Protamine Hagedorn Insulin
100%
Randomized Controlled Trial
100%
Metformin
100%
Bedtime
42%
Type 2 Diabetes Mellitus (T2DM)
42%
Glycemic Control
28%
Twice Daily
28%
Type 2 Diabetic Patients
14%
Hypoglycemia
14%
Mealtime
14%
Patient-completed
14%
Human Insulin
14%
Insulin Dose
14%
HbA1c Levels
14%
Between-group
14%
Glucose-lowering Drugs
14%
Weight Gain
14%
No Significant Difference
14%
Safety Profile
14%
Treatment Regimen
14%
Suboptimal Glycemic Control
14%
3-group
14%
Hemoglobin A1c (HbA1c)
14%
Medicine and Dentistry
Metformin Plus Repaglinide
100%
Randomized Controlled Trial
100%
Glycon
80%
Glycemic Control
60%
Type 2 Diabetes
60%
Hemoglobin A1c
40%
Hypoglycemia
20%
Human Insulin
20%
Repaglinide
20%
Biphasic Insulin
20%
Patient with Type 2 Diabetes
20%
Recombinant Human Insulin
20%
Pharmacology, Toxicology and Pharmaceutical Science
NPH Insulin
100%
Metformin Plus Repaglinide
100%
Biphasic Insulin
20%
Nursing and Health Professions
Metformin Plus Repaglinide
100%
Isophane Insulin
100%
Biphasic Insulin
20%